id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2096-0003,FDA,FDA-2022-E-2096,Letter to U S Patent and Trademark Office from FDA CDER,Other,Correspondence,2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T15:34:13Z,,0,0,09000064852f7ee0
FDA-2022-E-2096-0001,FDA,FDA-2022-E-2096,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:22:57Z,,0,0,090000648529dea5
FDA-2022-E-2096-0002,FDA,FDA-2022-E-2096,"Patent Extension Application from Merck Sharp & Dohme Corp. (on behalf of Peloton Therapeutics, Inc.)",Other,Application,2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:23:17Z,,0,0,090000648529dea8